Cas no 91679-37-7 (5-(1,1’-Biphenyl-4-ylphenylmethyl)-1H-imidazole)
5-(1,1’-Biphenyl-4-ylphenylmethyl)-1H-imidazole Chemical and Physical Properties
Names and Identifiers
-
- 1H-Imidazole, 4-([1,1'-biphenyl]-4-ylphenylmethyl)-
- 5-([1,1’-Biphenyl]-4-ylphenylmethyl)-1H-Imidazole
- 5-[phenyl-(4-phenylphenyl)methyl]-1H-imidazole
- 91679-37-7
- 5-[([1,1'-Biphenyl]-4-yl)(phenyl)methyl]-1H-imidazole
- 4-([1,1'-Biphenyl]-4-yl(phenyl)methyl)-1H-imidazole
- DTXSID80586251
- F81813
- 5-([1,1'-Biphenyl]-4-ylphenylmethyl)-1H-imidazole
- 5-([1,1'-BIPHENYL]-4-YL(PHENYL)METHYL)-1H-IMIDAZOLE
- AKOS005266655
- 4-([1,1'-Biphenyl]-4-ylphenylmethyl)1H-imidazole; Bifonazole EP Impurity B;
- 5-(1,1’-Biphenyl-4-ylphenylmethyl)-1H-imidazole
-
- Inchi: 1S/C22H18N2/c1-3-7-17(8-4-1)18-11-13-20(14-12-18)22(21-15-23-16-24-21)19-9-5-2-6-10-19/h1-16,22H,(H,23,24)
- InChI Key: IHKJGUSMXFFXBB-UHFFFAOYSA-N
- SMILES: N1C=NC=C1C(C1C=CC=CC=1)C1C=CC(C2C=CC=CC=2)=CC=1
Computed Properties
- Exact Mass: 310.146998583g/mol
- Monoisotopic Mass: 310.146998583g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 1
- Heavy Atom Count: 24
- Rotatable Bond Count: 4
- Complexity: 362
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 1
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 5.1
- Topological Polar Surface Area: 28.7?2
Experimental Properties
- Melting Point: >103oC (dec.)
- Solubility: Chloroform (Slightly), Methanol (Slightly)
5-(1,1’-Biphenyl-4-ylphenylmethyl)-1H-imidazole Security Information
- Storage Condition:Amber Vial, Refrigerator
5-(1,1’-Biphenyl-4-ylphenylmethyl)-1H-imidazole Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | B397925-5mg |
5-([1,1’-Biphenyl]-4-ylphenylmethyl)-1H-imidazole |
91679-37-7 | 5mg |
$ 159.00 | 2023-04-18 | ||
| TRC | B397925-10mg |
5-([1,1’-Biphenyl]-4-ylphenylmethyl)-1H-imidazole |
91679-37-7 | 10mg |
$ 242.00 | 2023-04-18 | ||
| TRC | B397925-50mg |
5-([1,1’-Biphenyl]-4-ylphenylmethyl)-1H-imidazole |
91679-37-7 | 50mg |
$ 973.00 | 2023-04-18 | ||
| TRC | B397925-100mg |
5-([1,1’-Biphenyl]-4-ylphenylmethyl)-1H-imidazole |
91679-37-7 | 100mg |
$ 1837.00 | 2023-04-18 | ||
| TRC | B397925-250mg |
5-([1,1’-Biphenyl]-4-ylphenylmethyl)-1H-imidazole |
91679-37-7 | 250mg |
$ 3608.00 | 2023-04-18 | ||
| A2B Chem LLC | AD15072-5mg |
1H-Imidazole, 4-([1,1'-biphenyl]-4-ylphenylmethyl)- |
91679-37-7 | 95 | 5mg |
$288.00 | 2024-07-18 | |
| Ambeed | A1524311-25mg |
4-([1,1'-Biphenyl]-4-yl(phenyl)methyl)-1H-imidazole |
91679-37-7 | 98% | 25mg |
$353.0 | 2025-04-15 | |
| Ambeed | A1524311-50mg |
4-([1,1'-Biphenyl]-4-yl(phenyl)methyl)-1H-imidazole |
91679-37-7 | 98% | 50mg |
$615.0 | 2025-04-15 | |
| Ambeed | A1524311-100mg |
4-([1,1'-Biphenyl]-4-yl(phenyl)methyl)-1H-imidazole |
91679-37-7 | 98% | 100mg |
$1014.0 | 2025-04-15 | |
| A2B Chem LLC | AD15072-25mg |
1H-Imidazole, 4-([1,1'-biphenyl]-4-ylphenylmethyl)- |
91679-37-7 | 98% | 25mg |
$360.00 | 2024-07-18 |
5-(1,1’-Biphenyl-4-ylphenylmethyl)-1H-imidazole Suppliers
5-(1,1’-Biphenyl-4-ylphenylmethyl)-1H-imidazole Related Literature
-
Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
-
Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
-
Jason Wan Lab Chip, 2020,20, 4528-4538
-
Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
Additional information on 5-(1,1’-Biphenyl-4-ylphenylmethyl)-1H-imidazole
Introduction to 5-(1,1'-Biphenyl-4-ylphenylmethyl)-1H-imidazole and Its Applications in Modern Chemical Biology
5-(1,1'-Biphenyl-4-ylphenylmethyl)-1H-imidazole, with the CAS number 91679-37-7, is a sophisticated organic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its intricate molecular structure, exhibits promising properties that make it a valuable candidate for various applications, particularly in drug discovery and molecular recognition.
The molecular framework of 5-(1,1'-Biphenyl-4-ylphenylmethyl)-1H-imidazole consists of a central imidazole ring substituted with a bulky biphenyl group and a phenylmethyl side chain. This structural configuration imparts unique electronic and steric properties, making it an attractive scaffold for designing novel bioactive molecules. The presence of multiple aromatic rings enhances its potential for π-stacking interactions, which are crucial in protein-ligand binding studies.
In recent years, there has been a surge in research focused on developing small-molecule inhibitors targeting various biological pathways. The imidazole moiety in 5-(1,1'-Biphenyl-4-ylphenylmethyl)-1H-imidazole has been extensively studied for its ability to interact with specific amino acid residues in proteins. This interaction is particularly relevant in the context of enzyme inhibition and receptor modulation, which are key strategies in modern drug design.
One of the most compelling aspects of this compound is its potential application in the development of kinase inhibitors. Kinases are a class of enzymes that play a critical role in cell signaling pathways and are often implicated in various diseases, including cancer. The biphenyl and phenylmethyl groups in the molecule provide a favorable pharmacophore for binding to the ATP-binding pockets of kinases, thereby inhibiting their activity. Recent studies have demonstrated that derivatives of imidazole-based compounds exhibit potent kinase inhibition properties, making them promising candidates for further development.
The structural features of 5-(1,1'-Biphenyl-4-ylphenylmethyl)-1H-imidazole also make it an excellent candidate for use as a tool compound in chemical biology research. Its ability to form stable complexes with biomolecules allows researchers to probe protein-ligand interactions at a molecular level. This capability is particularly valuable in understanding the mechanisms underlying various biological processes and in the development of targeted therapeutics.
In addition to its applications in kinase inhibition, 5-(1,1'-Biphenyl-4-ylphenylmethyl)-1H-imidazole has shown potential in other areas of pharmaceutical research. For instance, its structural motif has been explored as a scaffold for designing molecules that interact with G-protein coupled receptors (GPCRs). GPCRs are a large family of membrane receptors involved in numerous physiological processes, and targeting them has been a major focus in drug development over the past decades. The unique binding properties of this compound make it an intriguing candidate for further investigation.
The synthesis of 5-(1,1'-Biphenyl-4-ylphenylmethyl)-1H-imidazole presents an interesting challenge due to its complex structure. However, advances in synthetic chemistry have made it possible to access such molecules with high precision and yield. The synthesis typically involves multi-step reactions, including cross-coupling reactions and cyclization processes, which highlight the synthetic prowess required to produce this compound.
The pharmacological profile of this compound has been the subject of extensive computational and experimental studies. Molecular docking simulations have been used to predict how 5-(1,1'-Biphenyl-4-ylphenylmethyl)-1H-imidazole interacts with target proteins. These simulations have provided valuable insights into the binding mode and affinity of the compound towards various biological targets. Experimental validation through enzyme inhibition assays and protein binding studies has further corroborated these findings.
The potential therapeutic applications of 5-(1,1'-Biphenyl-4-ylphenylmethyl)-1H-imidazole extend beyond kinase inhibition. Preliminary studies have suggested that it may have anti-inflammatory properties by modulating inflammatory signaling pathways. Additionally, its ability to interact with DNA-binding proteins has raised interest in its potential as an anticancer agent. These findings underscore the versatility of this compound and its potential as a lead molecule for drug discovery.
The development of novel analytical techniques has also played a crucial role in studying 5-(1,1'-Biphenyl-4-ylphenylmethyl)-1H-imidazole. Techniques such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) have been instrumental in characterizing the compound's structure and purity. High-performance liquid chromatography (HPLC) has been used for its separation and purification from reaction mixtures.
In conclusion, 5-(1,1'-Biphenyl-4-ylphenylmethyl)-1H-imidazole, identified by CAS number 91679-37-7, is a multifaceted compound with significant potential in chemical biology and pharmaceutical research. Its unique structural features make it an excellent candidate for designing novel bioactive molecules targeting various biological pathways. The ongoing research into this compound highlights its importance as a tool molecule for understanding biological processes and developing new therapeutic agents.
91679-37-7 (5-(1,1’-Biphenyl-4-ylphenylmethyl)-1H-imidazole) Related Products
- 6918-06-5(Boranediamine,N,N'-diphenyl-1-(triphenylsilyl)-)
- 106147-80-2(1H-Imidazole,5-(2-[1,1'-biphenyl]-4-yl-2-phenylethyl)-)
- 106807-72-1(4-(1-(2,3-Dimethylphenyl)ethyl)-1H-imidazole hydrochloride)
- 113775-47-6(Dexmedetomidine)
- 86347-14-0(Medetomidine)
- 145108-58-3(Dexmedetomidine hydrochloride)
- 86347-15-1(Medetomidine hydrochloride)
- 881409-85-4(1H-Imidazole,5-(1-phenylethyl)-)
- 137967-81-8(1H-Imidazole,5-[1-(1-naphthalenyl)ethyl]-, hydrochloride (1:1))
- 119717-21-4(Levomedetomidine)